Dr. Lazarides on CRM1 as a Potential Target in Osteosarcoma

Video

Alexander Leandros Lazarides, MD, resident at Duke University Medical Center, discusses CRM1 as a potential target in osteosarcoma.

Alexander Leandros Lazarides, MD, resident at Duke University Medical Center, discusses CRM1 as a potential target in osteosarcoma.

In an in vitro cell line analysis of osteosarcoma, CRM1 inhibitors were found to be effective in killing cancer cells, says Lazarides. CRM1 is expressed across several different cells and cancer cell types, and higher expression confers a worse prognosis.

CRM1 is an essential nuclear export factor which transports products from the nucleus into the cytoplasm of the cell so that they can be processed into more functional proteins. In an in vivo trial in mice, a CRM1 inhibitor had a high effect on limiting tumor growth compared with controls, further validating CRM1 as a target in osteosarcoma, concludes Lazarides.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD